Stallergenes Sa (STLEF) 80.1000 $STLEF
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Global Cedar Pollen Allergy Pipeline Review 2014 - Analysis of 10 Companies & 13 Drug Profiles
M2 - Thu Apr 17, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks25jx/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Cedar Pollen Allergy - Companies Involved in Therapeutics Development - Taiho Pharmaceutical Co., Ltd. - Allergy Therapeutics plc - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Ltd - Anergis SA - REGiMMUNE Corporation - Immunomic Therapeutics, Inc. - Biomay AG - Adiga Life Sciences Inc. Drug Profiles - TAC-201 - Cry J1-galactomannan Conjugate - JRC-LAMP-Vax - TO-206 - Pollinex Quattro Japanese Cedar - RGI-1001 - Japanese Cedar Pollen Tablet - Japanese Cedar Hypoallergenic Vaccine - ToleroMune Japanese Cedar Allergy T Cell Vaccine - AllerJ - Vaccine for Cedar Pollen Allergy - Vaccine for Japanese Cedar Pollen Allergy - JCC-LAMP-Vax For more information visit http://www.researchandmarkets.com/research/ks...dar_pollen
Global House Dust Mite Allergy Pipeline Review Report 2014
M2 - Tue Apr 15, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/537l2n/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products House Dust Mite Allergy - Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Circassia Ltd - Genetic Immunity, Inc - Anergis SA - Biomay AG - Polyrizon Ltd. Drug Profiles - Allergenic pollen extract of timothy - MK-8237 - S-524101 - House Dust Mite-SPIRE - DermAll-HDM - House Dust Mite Allergen Peptide Carrier Fusion Vaccine - AllerDM - Viaskin House Dust Mite - Recombinant Protein for House Dust Mite Allergy - PL-103 For more information visit http://www.researchandmarkets.com/research/53..._dust_mite
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013
M2 - Thu Feb 20, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/mr7rjr/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Allergic Rhino-Conjunctivitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Unknown Stage Products Drug Profiles Pollinex Quattro Grass - Drug Profile MK-7243 - Drug Profile MK-3641 - Drug Profile grass pollen allergen extract - Drug Profile Pollinex Quattro Grass - Drug Profile MK-8237 - Drug Profile Grass Pollen Allergoid - Drug Profile Olea Europaea Pollen Extract - Drug Profile Modified Allergen Extract - Drug Profile AL-0704rP - Drug Profile Acaroid - Drug Profile Depigoid Birch - Drug Profile Recombinant Birch Pollen Allergen - Drug Profile Ragweed Pollen Extract - Drug Profile Avanz Phleum Pratense - Drug Profile CYT-003-QbG10 - Drug Profile gpASIT TM - Drug Profile ALK Birch Pollen Vaccine - Drug Profile Osiris - Drug Profile Phleum Pratense - Drug Profile JRC-LAMP Vax - Drug Profile bilastine - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned BioTech Tools ALK-Abello A/S FAES Farma SA Allergy Therapeutics plc Stallergenes S.A. Cytos Biotechnology AG Allergopharma Joachim Ganzer KG Greer Laboratories, Inc. Laboratorios LETI S.L. Immunomic Therapeutics, Inc. Bial - Portela & Ca, S.A. Roxall Medizin GmbH For more information visit http://www.researchandmarkets.com/research/mr7rjr/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cedar Pollen Allergy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3sxtk/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Cedar Pollen Allergy. - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cedar Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cedar Pollen Allergy Overview Therapeutics Development Cedar Pollen Allergy - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Cedar Pollen Allergy - Therapeutics Assessment Drug Profiles TO-194SL - Drug Profile TAC-201 - Drug Profile Cry J1-galactomannan Conjugate - Drug Profile JRC-LAMP Vax - Drug Profile TO-206 - Drug Profile Pollinex Quattro Japanese Cedar - Drug Profile RGI-1001 - Drug Profile Japanese Cedar Pollen Tablet - Drug Profile Japanese Cedar Hypoallergenic Vaccine - Drug Profile AllerJ - Drug Profile Cedar Pollen Vaccine - Drug Profile Vaccine For Japanese Cedar Pollen Allergy - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Taiho Pharmaceutical Co., Ltd. Allergy Therapeutics plc Stallergenes S.A. Torii Pharmaceutical Co., Ltd. Anergis SA REGiMMUNE Corporation Immunomic Therapeutics, Inc. Biomay AG Adiga Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/f3...dar_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research Report: Ragweed Allergy - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdfhh2/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H2 2013" report to their offering. 'Ragweed Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ragweed Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ragweed Allergy. Scope - A snapshot of the global therapeutic scenario for Ragweed Allergy. - A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ragweed Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned ALK-Abello A/S Allergy Therapeutics plc Stallergenes S.A. Circassia Holdings Ltd. ANERGIS SA Immunomic Therapeutics, Inc. Biomay AG For more information visit http://www.researchandmarkets.com/research/wd...ed_allergy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cedar Pollen Allergy - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wj83qr/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understand
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Global Allergic Rhino-Conjunctivitis Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vm88b/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A
House Dust Mite Allergy - Pipeline Review, H1 2013 Available Now
M2 - Tue Jun 04, 11:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdngvg/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for House Dust Mite Allergy. - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Holdings Ltd. - Genetic Immunity, LLC - ANERGIS SA - Bial - Portela & Ca, S.A. - Biomay AG For more information visit http://www.researchandmarkets.com/research/sd..._dust_mite About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rhinitis - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:21AM CDT
Research and Markets has announced the addition of the "Rhinitis - Pipeline Review, H1 2013" report to their offering. 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strateg
Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States
Marketwire Canada - Mon Apr 15, 4:00AM CDT
Ares Life Sciences, a healthcare-focused investment group, announced today that it has signed a definitive agreement to acquire 100% of the share capital of Planet Biopharmaceuticals, Inc., including its wholly owned subsidiary Antigen Laboratories, Inc., a producer of allergen extracts, who works closely with the ENT (Ear, Nose and Throat) specialist community in the United States. Closing of the transaction is subject to certain closing conditions.
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012 Gives a Clear Account of the Market
M2 - Mon Feb 18, 8:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/cdgh58/allergic) has announced the addition of Global Markets Direct's new report "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets D
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Global Cedar Pollen Allergy Pipeline Review 2014 - Analysis of 10 Companies & 13 Drug Profiles
M2 - Thu Apr 17, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks25jx/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Cedar Pollen Allergy - Companies Involved in Therapeutics Development - Taiho Pharmaceutical Co., Ltd. - Allergy Therapeutics plc - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Ltd - Anergis SA - REGiMMUNE Corporation - Immunomic Therapeutics, Inc. - Biomay AG - Adiga Life Sciences Inc. Drug Profiles - TAC-201 - Cry J1-galactomannan Conjugate - JRC-LAMP-Vax - TO-206 - Pollinex Quattro Japanese Cedar - RGI-1001 - Japanese Cedar Pollen Tablet - Japanese Cedar Hypoallergenic Vaccine - ToleroMune Japanese Cedar Allergy T Cell Vaccine - AllerJ - Vaccine for Cedar Pollen Allergy - Vaccine for Japanese Cedar Pollen Allergy - JCC-LAMP-Vax For more information visit http://www.researchandmarkets.com/research/ks...dar_pollen
Global House Dust Mite Allergy Pipeline Review Report 2014
M2 - Tue Apr 15, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/537l2n/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products House Dust Mite Allergy - Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Circassia Ltd - Genetic Immunity, Inc - Anergis SA - Biomay AG - Polyrizon Ltd. Drug Profiles - Allergenic pollen extract of timothy - MK-8237 - S-524101 - House Dust Mite-SPIRE - DermAll-HDM - House Dust Mite Allergen Peptide Carrier Fusion Vaccine - AllerDM - Viaskin House Dust Mite - Recombinant Protein for House Dust Mite Allergy - PL-103 For more information visit http://www.researchandmarkets.com/research/53..._dust_mite
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013
M2 - Thu Feb 20, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/mr7rjr/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Allergic Rhino-Conjunctivitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Unknown Stage Products Drug Profiles Pollinex Quattro Grass - Drug Profile MK-7243 - Drug Profile MK-3641 - Drug Profile grass pollen allergen extract - Drug Profile Pollinex Quattro Grass - Drug Profile MK-8237 - Drug Profile Grass Pollen Allergoid - Drug Profile Olea Europaea Pollen Extract - Drug Profile Modified Allergen Extract - Drug Profile AL-0704rP - Drug Profile Acaroid - Drug Profile Depigoid Birch - Drug Profile Recombinant Birch Pollen Allergen - Drug Profile Ragweed Pollen Extract - Drug Profile Avanz Phleum Pratense - Drug Profile CYT-003-QbG10 - Drug Profile gpASIT TM - Drug Profile ALK Birch Pollen Vaccine - Drug Profile Osiris - Drug Profile Phleum Pratense - Drug Profile JRC-LAMP Vax - Drug Profile bilastine - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned BioTech Tools ALK-Abello A/S FAES Farma SA Allergy Therapeutics plc Stallergenes S.A. Cytos Biotechnology AG Allergopharma Joachim Ganzer KG Greer Laboratories, Inc. Laboratorios LETI S.L. Immunomic Therapeutics, Inc. Bial - Portela & Ca, S.A. Roxall Medizin GmbH For more information visit http://www.researchandmarkets.com/research/mr7rjr/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cedar Pollen Allergy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3sxtk/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Cedar Pollen Allergy. - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cedar Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cedar Pollen Allergy Overview Therapeutics Development Cedar Pollen Allergy - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Cedar Pollen Allergy - Therapeutics Assessment Drug Profiles TO-194SL - Drug Profile TAC-201 - Drug Profile Cry J1-galactomannan Conjugate - Drug Profile JRC-LAMP Vax - Drug Profile TO-206 - Drug Profile Pollinex Quattro Japanese Cedar - Drug Profile RGI-1001 - Drug Profile Japanese Cedar Pollen Tablet - Drug Profile Japanese Cedar Hypoallergenic Vaccine - Drug Profile AllerJ - Drug Profile Cedar Pollen Vaccine - Drug Profile Vaccine For Japanese Cedar Pollen Allergy - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Taiho Pharmaceutical Co., Ltd. Allergy Therapeutics plc Stallergenes S.A. Torii Pharmaceutical Co., Ltd. Anergis SA REGiMMUNE Corporation Immunomic Therapeutics, Inc. Biomay AG Adiga Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/f3...dar_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research Report: Ragweed Allergy - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdfhh2/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H2 2013" report to their offering. 'Ragweed Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ragweed Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ragweed Allergy. Scope - A snapshot of the global therapeutic scenario for Ragweed Allergy. - A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ragweed Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned ALK-Abello A/S Allergy Therapeutics plc Stallergenes S.A. Circassia Holdings Ltd. ANERGIS SA Immunomic Therapeutics, Inc. Biomay AG For more information visit http://www.researchandmarkets.com/research/wd...ed_allergy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cedar Pollen Allergy - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wj83qr/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understand
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Global Allergic Rhino-Conjunctivitis Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vm88b/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A
House Dust Mite Allergy - Pipeline Review, H1 2013 Available Now
M2 - Tue Jun 04, 11:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdngvg/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for House Dust Mite Allergy. - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Holdings Ltd. - Genetic Immunity, LLC - ANERGIS SA - Bial - Portela & Ca, S.A. - Biomay AG For more information visit http://www.researchandmarkets.com/research/sd..._dust_mite About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rhinitis - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:21AM CDT
Research and Markets has announced the addition of the "Rhinitis - Pipeline Review, H1 2013" report to their offering. 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strateg
Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States
Marketwire Canada - Mon Apr 15, 4:00AM CDT
Ares Life Sciences, a healthcare-focused investment group, announced today that it has signed a definitive agreement to acquire 100% of the share capital of Planet Biopharmaceuticals, Inc., including its wholly owned subsidiary Antigen Laboratories, Inc., a producer of allergen extracts, who works closely with the ENT (Ear, Nose and Throat) specialist community in the United States. Closing of the transaction is subject to certain closing conditions.
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012 Gives a Clear Account of the Market
M2 - Mon Feb 18, 8:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/cdgh58/allergic) has announced the addition of Global Markets Direct's new report "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets D
